Moderna CEO Bancel Holds 30.38M Shares, Signals Confidence

TL;DR

**Moderna CEO Bancel still owns over 30 million shares, a bullish sign for the stock.**

AI Summary

Stéphane Bancel, CEO of Moderna, Inc., filed an amended SC 13G/A on February 7, 2024, disclosing his beneficial ownership of 30,384,866 shares of Moderna's common stock as of December 31, 2023. This represents a significant stake, indicating his continued confidence and alignment with the company's performance. Investors should note this as a strong signal from an insider, suggesting a belief in Moderna's future prospects.

Why It Matters

This filing shows that Moderna's CEO, Stéphane Bancel, maintains a substantial personal investment in the company, aligning his financial interests directly with those of other shareholders. It's a positive sign for investors, indicating strong insider conviction.

Risk Assessment

Risk Level: low — This filing indicates a stable, significant insider holding, which generally reduces perceived risk due to strong alignment of interests.

Analyst Insight

A smart investor would view Stéphane Bancel's substantial and stable ownership of 30,384,866 shares as a strong indicator of insider confidence, potentially reinforcing a bullish outlook on Moderna's long-term prospects.

Key Numbers

• 30,384,866 — Shares Beneficially Owned (Stéphane Bancel's sole voting and dispositive power over Moderna common stock as of December 31, 2023.)
• December 31, 2023 — Date of Event (The date for which the beneficial ownership was reported.)
• February 7, 2024 — Filing Date (The date the SC 13G/A amendment was filed with the SEC.)

Key Players & Entities

• Stéphane Bancel (person) — Reporting Person, CEO of Moderna, Inc.
• Moderna, Inc. (company) — Subject Company, issuer of the securities
• BOSTON BIOTECH VENTURES, LLC (company) — Group Member
• OCHA LLC (company) — Group Member
• 03 Life Sciences (company) — Organization Name

Forward-Looking Statements

• Stéphane Bancel will maintain a significant ownership stake in Moderna, reflecting continued long-term commitment. (Stéphane Bancel) — high confidence, target: December 31, 2024

FAQ

From the Filing

0001193125-24-025972.txt : 20240207 0001193125-24-025972.hdr.sgml : 20240207 20240207084256 ACCESSION NUMBER: 0001193125-24-025972 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 GROUP MEMBERS: BOSTON BIOTECH VENTURES, LLC GROUP MEMBERS: OCHA LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-90749 FILM NUMBER: 24602325 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Bancel Stephane CENTRAL INDEX KEY: 0001443340 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 320 BENT STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 SC 13G/A 1 d752423dsc13ga.htm SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934* (Amendment No. 5) Moderna, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60770K 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 60770K107  1.   Names of Reporting Person  Stéphane Bancel  2.  Check the Appropriate Box if a Member of a Group (See Instructions)  (a) ☐  (b) ☒  3.  SEC Use Only  4.  Citizenship or Place of Organization  France Number of Shares  Beneficially  Owned by Each Reporting Person With 5.   Sole Voting Power  30,384,866 (1) 6.  Shared Voting Power  0 7.  Sole Dispositive Power  30,384,866 (1) 8.  Shared Dispositive Power  0  9.   Aggregate Amount Beneficially Owned by Each Reporting Person  30,384,866 (1) 10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐ 11.  Percent of Class Represented by Amount in Row (9)  7.8% (2) 12.  Type of Reporting Person (See Instructions)  IN (1) Consists of (i) 5,429,839 shares of Common Stock held directly by Mr. Bancel, (ii) 9,339,775 shares issuable to Mr. Bancel upon exercise of share options exercisable within 60 days after December 31, 2023, (iii) 6,564,880 shares of Common Stock held by OCHA LLC, and (iv) 9,050,372 shares of Common Stock held by Boston Biotech Ventures, LLC. (2) Percentage ownership is calculated based on (i) 381,794,720 shares of Common Stock outstanding as of December 31, 2023 and (ii) 9,339,775 shares of Common Stock underlying the share options held by Mr. Bancel that are exercisable within 60 days of December 31, 202